Star Combo Pharma Limited (ASX:S66)
Australia · Delayed Price · Currency is AUD 0.1400
0.00 (0.00%)
Sep 3, 2026, 4:10 PM AEST
Star Combo Pharma Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 23.57 | 27.81 | 26.02 | 24.7 | 22.88 |
Other Revenue | - | - | - | - | 0.08 |
| 23.57 | 27.81 | 26.02 | 24.7 | 22.96 | |
Revenue Growth | -15.24% | 6.89% | 5.34% | 7.57% | -14.86% |
Cost of Revenue | 17.79 | 21.54 | 20.3 | 19.91 | 18.79 |
Gross Profit | 5.78 | 6.27 | 5.71 | 4.79 | 4.17 |
Selling, General & Admin | 6.01 | 6.51 | 4.84 | 3.79 | 4.54 |
Other Operating Expenses | -0.24 | -5.24 | -0.2 | -0.16 | -0.3 |
Operating Expenses | 5.77 | 1.27 | 4.79 | 3.66 | 4.24 |
Operating Income | 0.01 | 5 | 0.92 | 1.12 | -0.06 |
Interest Expense | -0.2 | -0.19 | -0.2 | -0.19 | -0.17 |
Interest & Investment Income | 0.63 | 0.43 | 0.26 | 0.13 | 0.05 |
Currency Exchange Gain (Loss) | 0.09 | 0.08 | 0.01 | -0.05 | 0.05 |
Other Non Operating Income (Expenses) | - | -0 | 0 | - | 0 |
EBT Excluding Unusual Items | 0.53 | 5.31 | 1 | 1.02 | -0.14 |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.09 |
Asset Writedown | - | - | - | -4.41 | -1.46 |
Legal Settlements | - | - | - | -0.06 | - |
Other Unusual Items | - | - | - | - | 0.6 |
Pretax Income | 0.53 | 5.31 | 1 | -3.45 | -1.08 |
Income Tax Expense | 0.13 | 0.06 | 0.25 | 0.55 | -0.39 |
Net Income | 0.39 | 5.25 | 0.75 | -4 | -0.7 |
Net Income to Common | 0.39 | 5.25 | 0.75 | -4 | -0.7 |
Net Income Growth | -92.48% | 602.32% | - | - | - |
Shares Outstanding (Basic) | 135 | 135 | 135 | 135 | 135 |
Shares Outstanding (Diluted) | 135 | 135 | 135 | 135 | 135 |
Shares Change | - | - | - | 0.37% | -0.15% |
EPS (Basic) | 0.00 | 0.04 | 0.01 | -0.03 | -0.01 |
EPS (Diluted) | 0.00 | 0.03 | 0.01 | -0.03 | -0.01 |
EPS Growth | -90.26% | 442.28% | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 0.82 | 11.55 | -1.76 | -0.85 | -6.76 |
Free Cash Flow Per Share | 0.01 | 0.09 | -0.01 | -0.01 | -0.05 |
Dividend Per Share | - | 0.004 | 0.004 | - | - |
Dividend Growth | - | 0% | - | - | - |
Gross Margin | 24.52% | 22.55% | 21.96% | 19.38% | 18.18% |
Operating Margin | 0.04% | 17.98% | 3.55% | 4.55% | -0.28% |
Profit Margin | 1.67% | 18.87% | 2.87% | -16.21% | -3.03% |
Free Cash Flow Margin | 3.49% | 41.52% | -6.76% | -3.44% | -29.45% |
EBITDA | 1.22 | 6.64 | 1.73 | 1.63 | 0.37 |
EBITDA Margin | 5.17% | 23.86% | 6.65% | 6.59% | 1.59% |
D&A For EBITDA | 1.21 | 1.64 | 0.81 | 0.51 | 0.43 |
EBIT | 0.01 | 5 | 0.92 | 1.12 | -0.06 |
EBIT Margin | 0.04% | 17.98% | 3.55% | 4.55% | -0.28% |
Effective Tax Rate | 25.33% | 1.20% | 25.35% | - | - |